Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant endocrine tumour syndrome characterised by three main manifestations which are primary hyperparathyroidism (78-94%), gastroenteropancreatic neuroendocrine tumours (GEP-NETs) (35-78%) and pituitary adenomas
(20-65%). 1 As described, GEP-NETs are the second most common component of MEN1 syndrome and metastatic GEP-NETs are shown to be related with poor prognosis. 2 For metastatic and inoperable GEP-NETs, there are some interventional and medical therapies. Peptide receptor radionuclide therapy (PRRT) with Yttrium-90 ( 90 Y) and Lutetium-177 ( 177 Lu) is one of the important radiotherapies; however, there have been no randomised controlled study evaluating both efficacy and safety of 177 Lu-DOTATATE since 2017. The recently published NETTER-1 study demonstrated the markedly longer progression-free survival (PFS) with 177 Lu-DOTATATE treatment in midgut NETs. 3 In this case report, we describe a patient with MEN1 syndrome with inoperable metastatic GEP-NETs who had excellent response to the treatment with six cycles of 177 Lu-DOTATATE.
Case report
A 35-year-old male patient was admitted to our clinic with widening of hands and feet, polyuria, polydipsia, nausea, vomiting and constipation in 2008. He had a history of hydrocephalus diagnosis when 2 months old. Physical examination showed normal vital signs and findings, except coarsening of voice and large tongue, nose, hands and feet. Laboratory findings revealed low total testosterone (0.14 ng/mL), luteinising hormone (0.66 mIU/mL) and follicle stimulating hormone (2.24 mIU/mL); elevated Insulin like growth factor-1 (IGF-1) (662 ng/mL; according to age-and sex-specific serum IGF-1 levels), growth hormone (GH) (22.7 ng/mL), and calcium (11.0 mg/dl); and intact parathyroid hormone concentration (160 pg/mL) with low phosphate concentration (2.1 mg/dl). Twenty-four-hour urinary calcium excretion was elevated (399 mg/day). Additionally, bone mineral density was also decreased; L1-L4 anteroposterior spine T-and Z-scores were -3.4 SD and -4.2 SD, respectively. Scanning with Technetium-99m-hexakis 2-methoxyisobutyi isonitrile sesta ( 99m Tc-MIBI) demonstrated a focal area of increased activity at the left thyroid lobe inferior-pole region, suggestive of a parathyroid adenoma. These findings, including non-suppressed GH levels by oral glucose tolerance test (OGTT), were compatible with primary hyperparathyroidism, acromegaly and secondary hypogonadism; as a result, he was diagnosed with MEN1 syndrome. He was also diagnosed with central diabetes insipidus by an overnight water deprivation test. Pituitary magnetic resonance imaging (MRI) revealed a 19 mm pituitary macroadenoma without compression of optic chiasm and he was operated on by transsphenoidal route.
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M ultiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant endocrine tumour syndrome characterised by three main manifestations: primary hyperparathyroidism (78-94%), gastroenteropancreatic neuroendocrine tumours (GEP-NETs) (35-78%) and pituitary adenomas (20-65%). For metastatic and inoperable GEP-NETs, there are some interventional and medical therapies. Peptide receptor radionuclide therapy (PRRT) with Yttrium-90 ( 90 Y) and Lutetium-177 ( 177 Lu) is one of the important radiotherapies. Herein we describe a case of MEN1 syndrome with inoperable metastatic GEP-NETs who had excellent response to the treatment with six cycles of 177 Lu-DOTATATE. The patient was admitted to our clinic with widening of hands and feet, polyuria, polydipsia, nausea, vomiting and constipation. His laboratory and screening findings were consistent with primary hyperparathyroidism, acromegaly, secondary hypogonadism and central diabetes insipidus. He underwent 3.5 parathyroidectomy and hypophysis adenomectomy. Under treatment with lanreotide and cabergoline, he developed metastatic duodenal NET. PRRT with 177 Lu-DOTATATE was administered in six cycles and an excellent response was displayed without any side effect. In conclusion, the dramatic response of the patient to PRRT with 177 Lu-DOTATATE, described in our case report and recent published articles indicating the beneficial efficacy and limited adverse effects of 177 Lu-DOTATATE, should encourage clinicians to use PRRT for inoperable or metastatic NETs.
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